SPL-23-ASO

N/A

Report date: 2022/11/11 17:16:53

Base Information

Drug NameSPL-23-ASO

Drug Alias Nameantisense oligonucleotide consisting of 18 nucleotide residues with a sequence of 5ďż˝-5MeC-5MeU-5MeU-5MeU-5MeC-5MeC-5MeU-5MeU-5MeC-A-5MeC-5MeU-G-5MeU- 5MeU-G-5MeC-A-3ďż˝SPL-23-ASOSPL-232SPL-23

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionRNA interferenceCystic fibrosis transmembrane conductance regulator modulators

TargetsCystic fibrosis transmembrane conductance regulator

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSplisense Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSplisense Ltd

Inactive CompaniesN/A

Active IndicationsCystic Fibrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A